Please view our cookie policy that explains what cookies are and how they are used on our website. This also provides you with a guide on how to disable cookies, but please be aware that parts of the site will not function correctly if you disable them.

By closing this message, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

North Cumbria University Hospitals NHS Trust - 70 years of the NHS

Home > Our services > Denis Burke

Denis Burke


Gastroenterology and G(I)M

Based at

West Cumberland Infirmary and Cumberland Infirmary
Secretary contact - 01228 814138

Year qualified


Professional qualifications

MBBS (Bachelor of Medicine and Bachelor of Surgery); MD Doctor of Medicine;  Fellow of the Royal College of Physicians; Fellow of the Royal College of Physicians of Edinburgh

Treatment and procedures

Upper and lower GI endoscopy, IBD, liver disease, including viral hepatitis and general gastroenterology

Clinical Interests / specialist areas

IBD;hepatology; service development

Professional membership

British Medical Association; British Society of Gastroenterology; British Association for the Study of the Liver; Scottish Society of Gastroenterology; Association of Physicians


IBD, hepatology , dyspepsia and endoscopy


Dickinson Scholarship June1980 (Clinical surgery examination)

Leeds Gut Club, 1986 best presentation

"The potentially pathogenic character of Escherichia coli in inflammatory bowel disease" 

Astra Research Prize, 1988

Northern Region,1988

"Cardio-respiratory changes during diagnostic and therapeutic     ERCP"

David Dickson Research Prize 1990 for research in the Northern Region.

"A method of enhancing cytotoxin production to aid the detection of verocytotoxin producing E. coli and the application of the technique to the study of community acquired diarrhoea and ulcerative colitis"

£14,000 grant from the Northern Region Research Committee for the study of E. coli rough mutants in PBC

grant of £50,000 to provide a laser service at the Cumberland Infirmary, by the JP Dunne Will Medical Trust

Honorary Senior clinical lecturer University of Newcastle upon Tyne


Published Abstracts

Burke DA and Axon ATR. Adhesive E. coli in ulcerative colitis. Gut 1985; 26: A1156

Burke DA and Axon ATR. HeLa and Buccal epithelial cells in the detection of adhesive E. coli in ulcerative colitis. Digestive Diseases and Sciences 1986; 31: 170S

Burke DA and Axon ATR. Potentially pathogenic character of E. coli   in inflammatory bowel disease. Digestive diseases and Sciences 1986; 31: 170S

Burke DA and Axon ATR. The hydrophobic adhesion of E. coli in ulcerative colitis. Digestive Diseases and Sciences 1986; 31: 457S

Burke DA, Clayden SA, Lacey RW, Axon ATR. Eradication of adhesive E. coli   in ulcerative colitis (UC). Gut 1986; 27: A1257

Burke DA and Axon ATR. Hydrophobic adhesion of E. coli   (EC) in ulcerative colitis (UC). Gut 1986; 27: A1262

Burke DA and Axon ATR. Clostridium difficile (CD) and ulcerative colitis (UC). Gut 1986; 27: A1272

Burke DA and Axon ATR. Potentially pathogenic character of E. coli   (EC) in inflammatory bowel disease. Gut 1986; 27: A1275

Burke DA, Clayden SA, Dixon MF, Axon ATR, Lacey RW. Oral tobramycin improves the outcome of acute ulcerative colitis (UC). Gut 1987; 28: A1390

Foster PN, Lobo AJ, Burke DA, Johnston D, Axon ATR. Azathioprine in resistant ulcerative colitis. Gut 1988; 29: A1474

Burke DA, Seed K, Mitchell KW, Record CO. Therapeutic reversal of coma and normalisation of the visual evoked potential (VEP) in hepatic encephalopathy. Gastroenterology International 1988; 1: 763

Record CO, Burke DA, Al Jumaili B. Clostridium difficile associated diarrhoea in adults. Gastroenterology International 1988; 1: 7645

Al Mardini H, Burke DA, Al Jumaili B, Record CO. The effect of protein and lactulose on the production of gamma amino butyric acid by faecal Escherichia coli . Gut 1989; 30: A1495

Lobo AJ, Burke DA, Sobala GM, Dixon MF, Axon ATR. Oral tobramycin in ulcerative

colitis: Effect on maintenance of remission. Gut 1991;32:A578

Burke DA, Al Jumaili B, Record CO. Enhancement of toxin production by 

verocytotoxin producing Escherichia coli : Application of technique to community

acquired diarrhoea. Gut 1991;32:A592

Burke D, Jackson D, Gould K, Freeman R, Bassendine MF, James OFW.

Primary Biliary Cirrhosis (PBC): No evidence to support a role for enterobacteriaceal Rough (R) Mutants in its aetiology. Hepatology 1991:14(2) suppl;62A

Hugh TJ, Birt MC, Burke DA, Dyson P, Raimes SA. Intraluminal radiotherapy for the palliation of dysphagia in patients with inoperable carcinoma of the proximal stomach. Gut 1995;36:A45

Ashley BD and Burke DA. The epidemiology of PBC- the Pennine Divide? Gut 1999;45: (suppl V) A8

Burke DA and Todd A. Use or abuse of H pylori serology in the management of dyspepsia. Gut 2000; 47 A121.

Edge V and Burke DA Patient perception of their disease and its treatment in IBD. Gut 2000;47:A229

Baragiotta AM et al Craig WL, James OFW, Mitchison HC, Burke DA, Bateson M, Trewby PN, Macklon AF Bassendine MF. Validation of the revised international autoimmune hepatitis group IIAHG) scoring system: Experience in the North of England. Gut 2001;48:A108

Singh J and Burke DA. An audit of faecal occult blood tests in a District General Hospital. Gut 2001;48:A53

A.M. Baragiotta, W. Craig, O. James, H. Mitchison, D. Burke, M. Bateson, P. Trewby, M. Bassendine. Is the revised International Autoimmune Hepatitis group (IAHG) scoring system useful ? J Hepatol. 2001:34; suppl:331A.

A..M. Baragiotta, W. Craig, O. James, H. Mitchison, D. Burke, M. Bateson, P. Trewby, A. Macklon, M.F. Bassendine. Autoimmune hepatitis (AIH) in men. J Hepatol. 2001:34:suppl;369A

Singh J.N. and Burke D.A. Use or abuse of faecal occult bloods (FOB’s). Gut 2001;49

(Suppl III) 1285

Hawthorne AB, Travis SPL, and BSG IBD Clinical Network. Outcome of in-patient management of severe colitis - a BSG IBD clinical network survey. Gut 2002:50 (Suppl II) A16

Edge V, Macdonald C, Raimes S, Edgar A, Honeyman J, Keyes I, Burke D.

“Test and Treat” - A Pilot study of a community based nurse led C13 urea breath test (C13UBT) service in Cumbria. Gut 2002:50 (Suppl II) A63

Edge V, Macdonald C and Burke DA. Follow up – time to change? The patients view.

Gut 2002 :50 (Suppl II) A78

Harrison R, Todd A, Holt K, Burke D. Hepatitis C, rural areas have “icebergs” too!

Gut 2004:53 (Suppl III) A82

Probert C, Marteau P, Ford J, Rademaker J, Parkes M, Forbes A, Riley S, Burke D, Tham TCK, Foldager M. Topical 5-ASA can be added to high dose (4g) oral therapy without significant changes to urinary concentrations of 5-ASA and acetyl-5-ASA or evidence of renal adverse effects. Gut 2005

Hearnshaw S, Burke DA. Under performing or under funding? a survey of practice in upper gastrointestinal bleeding . Gut 2005

Shenderey RL, Harrison R, Burke DA. Hepatitis C - a weighty economic problem? Gut 2005

Johnson GJ, Edge V, Palmer J, Burke DA. Audit of colonoscopy surveillance waiting list in a district general hospital: The benefit of BSG guidelines. Gut supplement 11 A8 2006

Parr J, Burke DA, Macdonald CE. A rash can cause GI bleeding. Gut supplement 11 A31 2006


Ramos JM, Burke DA, Veitch PS. Hernia of Morgagni in patients on continuous ambulatory peritoneal dialysis. Lancet 1982; I: 161

Burke DA, Stoddart JC, Ward MK, Simpson CGB. Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide. British Medical Journal 1982; 285: 696

Juby LD, Burke DA, Axon ATR. Somatostatin analogue SMS 201 995. Long term therapy for Vipoma. Postgraduate Medical Journal 1987; 63: 287 289

Burke DA, Manning AP, Williamson JMS, Axon ATR. Adverse reactions to sulphasalazine and 5 amino salicylic acid in the same patient. Alimentary Pharmacology & Therapeutics 1987; 1: 201 208

Burke DA and Axon ATR. Ulcerative colitis and E. coli with adhesive properties. Journal of Clinical Pathology 1987; 40: 782 786

Burke DA and Axon ATR. HeLa and buccal epithelial cell adhesion assays for detecting intestinal E. coli with adhesive properties in ulcerative colitis. Journal of Clinical Pathology 1987; 40: 1402 4

Burke DA and Axon ATR. Clostridium difficile, sulphasalazine, and ulcerative colitis. Postgraduate Medical Journal 1987; 67: 955 7

Burke DA, Axon ATR. Hydrophobic adhesin of E. coli in ulcerative colitis. Gut 1988; 29: 41 3

Burke DA, Manning AP, Murphy L, Axon ATR. Oral bowel lavage preparation for colonoscopy. Postgraduate Medical Journal 1988; 64: 772 4

Burke DA, Axon ATR. Adhesive Escherichia coli   in inflammatory bowel disease and infective diarrhoea. British Medical Journal 1988; 297: 102 4

Dixon MF, Wyatt JJ, Burke DA, Rathbone BJ. Lymphocytic gastritis   relationship to Campylobacter pylori infection. Journal of Pathology 1988; 154: 125 32

Burke DA, Clayden SA, Axon ATR. Sulphasalazine does not select for Escherichia coli   with adhesive properties in ulcerative colitis. Lancet 1988; ii: 966

Burke DA, Mitchell KW, Al Mardini H, Record CO. Reversal of hepatic coma with Flumazenil with improvement in visual evoked potentials. Lancet 1988; ii: 505 6

Burke DA. What causes Crohn's disease? The Body Report. Part 4. Observer 1988

Burke DA, Dixon MF, Axon ATR. Ulcerative colitis: Prolonged remission following Azathioprine induced pancytopenia. Journal of Clinical Gastroenterology 1989; 11: 327 30

Daly MJ, Forret EA, Carroll NJH, Gallon KRW, Plaat FS, Persoff DA, Isitt TVT, Wilkins DC, Knight SM, Nightingale J, Burke DA, Mitchison H, O'Brian S, Rich A, Clague MB. Munchausen Zollinger Ellison syndrome. Lancet 1989; I: 853

Lobo AJ, Foster PN, Burke DA, Johnston D, Axon ATR. The role of Azathioprine in the management of ulcerative colitis. Diseases of the Colon and Rectum 1990; 33: 374 377

Burke DA, Imray E, Record CO. Yersinia enterocolitica infection as a presenting feature of primary haemochromatosis. European Journal of Gastroenterology and Hepatology 1990; 2: 161 162

Burke DA, Clayden SA, Axon ATR. Serum bactericidal resistance of faecal E. coli and bactericidal competence of serum from patients with ulcerative colitis. Journal of Clinical Pathology 1990; 43: 316 319

Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 1990; 4: 123 129

Burke DA and James OFW. Clinical assessment of liver disease. Medicine International 1990; 83:3412 3416

Burke DA and Axon ATR. Adhesive E. coli in ulcerative colitis. In: Ulcerative colitis. Editor Colm O'Morain. CRC Press 1991 pp9-21.

Al Mardini H, Al Jumaili B, Record CO, Burke DA. The effect of protein and lactulose on the production of gamma amino butyric acid by faecal E. coli . Gut 1991;32:1007-1010

Al Jumaili I, Burke DA, Scotland SM, Al Mardini H, and Record CO. A method of enhancing verocytotoxin production by Escherichia coli. FEMS Microbiology Letters 1992;93:121-126

Schmeuli E, Myszor MF, Burke D, Record CO, Matthewson K. Limitations of laser treatment for malignant dysphagia. British Journal of Surgery, 1992. 79(8):778 80

Burke D, Al Jumaili BJ, Al Mardini H, Record CO. Culture negative Cytotoxin positive stools in community acquired diarrhoea. Gut 1993;34:192 193

Lobo AJ, Burke DA, Sobala GM, Axon ATR. Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Alimentary Pharmacology & Therapeutics. 1993;7:155 158

Hawthorne AB, Record CO, Holdsworth CD, Giaffer MH, Burke DA, Keech ML, Hawkey CJ. Double blind trial of oral fluticasone propionate v prednisolone in active ulcerative colitis. Gut 1993;34:125 128.

Larner AJ, Dyer RG, Burke DA et al. Fulminant hepatic failure complicating exertional heat stroke with rhabdomyolysis. Eur J Gastroenterol Hepatol. 1993;5:55 58

Larner AJ and Burke DA. Heatstroke and its manifestations. American Journal of Gastroenterology.1993;88:787

Burke DA. Endoscopic Procedures. In, Guide to Hospital Diagnostic Procedures:Gastroenterology. Haymarket Medical Imprint 1993

International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581

Burke D. Escherichia coli and ulcerative colitis. J R Soc Med 1997;90:612-617

Burke D. In MCQs in Clinical Gastroenterology. Petroc Press.UK.Ed Bateson M 1998

Burke D. In MCQs on the Upper Digestive Tract.Petroc Press UK Ed Bateson M 1999

Prince MI, Mitchison HC, Ashley D, Burke DA, Edwards N, Bramble MG, James OF, Jones DE. Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre randomised placebo-controlled cross-over trial. Alimentary Pharmacol Ther. 2003 Jan 17(1): p. 137-43

 Shenderey RL, Burke DA. Hepatitis C - A weighty economic problem? Gastroenterology Today 2005; 15 (4).

John Parr, Denis Burke and Vinoda Sharma. IVC Thrombosis and Crohn’s disease. Gastroenterology Today 2007; 17(3): 70-74

Miles Parkes, Jeffrey C Barrett, Natalie J Prescott, Mark Tremelling, Carl A Anderson, Sheila A Fisher, Roland G Roberts, Elaine R Nimmo, Fraser R Cummings, Dianne Soars, Hazel Drummond, Charlie W Lees, Saud A Khawaja, Richard Bagnall, Denis A Burke, Catherine E Todhunter, Tariq Ahmad, Clive M Onnie, Wendy McArdle, David Strachan, Graeme Bethel, Claire Bryan, Cathryn M Lewis, Panos Deloukas, Alastair Forbes, Jeremy Sanderson, Derek P Jewell, Jack Satsangi, John C Mansfield, the Wellcome Trust Case Control Consortium, Lon Cardon & Christopher G Mathew.

Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics; 2007 39: 830 – 832

Clark, L and Burke D. Alfuzosin induced liver failure. Gastroenterology Today 2008;18(1):20-22

Swann RE, Porras-Perez P, Burke DA. A hepato-renal diagnosis. Gastroenterology Today 2010; 20(3): 74-76

Francis S and Burke D. Abnormal LFTs, size or treatment? Sibutramine and abnormal LFTs. Gastroenterology Today 2011; 21(1) 16-17

Bevan R, Burke D. Ketamine as a possible cause of cirrhosis in a patient with chronic pain

Frontline Gastroenterology